Chronic infection with hepatitis B virus (HBV) increases the risk of developing fibrosis, cirrhosis or hepatocellular carcinoma. Current therapies are limited to type-I interferons and/or nucleos(t)ide analogues; however, these are only partially effective. The development of novel anti-HBV agents for new treatment strategies has been hampered by the lack of a suitable system that allows the in vitro replication of HBV. Studies of virus infection/replication at the molecular level using wild-type HBV are labor-intensive and time-consuming. To overcome these problems, we previously constructed a recombinant reporter HBV bearing the NanoLuc gene and showed its usefulness in identifying factors that affect HBV proliferation. Because this system mimics the early stage of the HBV life cycle faithfully, we conducted a quantitative analysis of HBV infectivity to several human hepatocyte cell lines as well as the effect of dimethyl sulfoxide and HBV protein X on the early stage of HBV proliferation using this system. Furthermore, we developed a system to produce a reporter HBV expressing a pol gene. These reporter HBV may provide an opportunity to enhance our understanding of the HBV life cycle and aid strategies for the development of new anti-HBV agents. -
| INTRODUCTION
Chronic infection with hepatitis B virus (HBV) affects nearly 240 million people worldwide, and increases their risk of developing fibrosis, cirrhosis or hepatocellular carcinoma. 1 Current therapies are limited to type-I interferon and/or nucleos(t)ide analogues, but these are only partially effective. The development of anti-HBV agents for new treatment strategies has been hampered by the lack of a suitable in vitro HBV replication system.
The study of virus infection/replication at the molecular level using wild-type virus is time consuming and labor-intensive. Moreover, exploring antivirals using high-throughput screening demands rapid, sensitive and quantitative methods, which wild-type virus, especially HBV, does not always tolerate. Although HBV replication mechanisms have been reported using genetic and biochemical approaches, 2 simple in vitro infection systems were limited to human primary hepatocytes and their derivative cell line HepaRG 3 until the recent discovery of the HBV receptor, sodium taurocholate co-transporting polypeptide, NTCP. 4 NTCP-transduced human hepatocytes have been used to derive cell lines including HepG2 and HuH7, which are susceptible to HBV infection in vitro. 5 However, despite the increased availability of HBV infectious cell lines, assays of wildtype HBV infection and replication are still time consuming and laborious.
Compared with wild-type HBV, reporter-expressing viruses offer advantages such as reduced labor and the effective screening of anti-HBV agents for the quantitative analysis of HBV infection/replication.
There have been numerous intensive attempts to engineer reporter HBV. However, the HBV genome is compact and contains indispensable cis-elements, forming approximately one-third of the genome, and which are clustered closely together between the C-terminal part of polymerase and the N-terminal of the core. These factors limit the size of pregenomic RNA (pgRNA) that can be packaged, the location of the insertion site, and the size of foreign genes inserted when engineering recombinant virus HBV. ing that these regions tolerate the insertion of foreign genes. [6] [7] [8] [9] [10] [11] [12] We previously developed a reporter HBV bearing the NanoLuc (NL) gene, which replaced 562 nucleotides of the core ORF, for the quantitative analysis of HBV infection/replication and for high throughput screening of anti-HBV agents. 5 The production of HBV/ NL from HepG2/NTCP#22 cells bearing pHBV/NL and pHBV/D, a helper plasmid that provides missing virus proteins in HBV/NL, was approximately one-fifth that of wild-type HBV produced from the same cell line bearing a plasmid that produces wild-type HBV.
Because NL is approximately 100-fold brighter than firefly (Photinus pyralis) or Renilla reniformis luciferase, HBV/NL allows the quantitative analysis of the HBV life cycle with high sensitivity and overcomes the low virus production for the quantitative analysis of HBV life cycle and high throughput screening.
NanoLuc activity of HBV/NL in virus-infected cells represents the amount of cellular HBV RNA, especially RNA transcribed from the preCore promoter. 5 Thus, this system is applicable for the analysis of various aspects of HBV entry/replication even to the level of HBV RNA. Indeed, using HBV/NL, we identified host factors that affected the entry of HBV and the transcription of its life cycle. 5 We used this advantage of HBV/NL to study HBV replication. We evaluated the role of HBV X protein in the early events of HBV life cycle and the effect of dimethyl sulfoxide on HBV infection and its proliferation, as well as monitoring HBV susceptible cells. We also constructed a reporter HBV bearing the entire pol coding sequence and examined its use in the HBV life cycle.
| MATERIALS AND METHODS

| Cells
Cells used in this work are described previously. 5 Briefly, human hepatocyte-derived cell lines were cultured in DMEM (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/mL penicillin, 100 lg⁄mL streptomycin and 100 U/mL nonessential amino acids (Life Technologies). HepG2/NTCP#22 and HuH7/NTCP cells are HepG2-derived and HuH7-derived cell lines transduced by pcNTCP-myc. Primary human hepatocytes (PHH), PXB cells, isolated from urokinase-type plasminogen activator transgenic/SCID mice inoculated with PHH (PhoenixBio, Hiroshima, Japan), were cultured in the medium according to the manufacturer's protocol.
| Plasmids
Hepatitis B virus genotype C cloned into pUC19, pUC1.2xHBV, was used (accession number AB246345). pHBV/NL was constructed as described previously 5 and pHBV/NL-X ter2, respectively. These mutations do not alter pol coding amino acid residues. HBV/NL-X ter1 and HBV/NL-X ter2 have putative ORF for 7 amino acid residues from the initiator codon and for 76 or 25 amino acid residues from the second methionine in the wild-type X coding frame, respectively. The HBV X expressing plasmid, pCAG X, was constructed by inserting the entire X coding sequence of HBV downstream of the CAG promoter.
| Production of recombinant virus
Plasmids encoding the HBV genome carrying a reporter gene were co-transfected with a helper virus expressing plasmid(s) to HepG2 or HuH7 cells using Lipofectamine 3000 (Life Technologies). Preparation of virus in medium was described previously. 
| Hepatitis B virus X enhances hepatitis B virus/NanoLuc infection
It is well documented that HBV X protein, HBV X, exerts various effects on HBV infection/replication and the fate of HBV infected cells. 12 We examined the effect of HBV X by taking advantage of the HBV/NL system. We prepared X-mutated HBV/NL, HBV/NL-X ter1 and HBV/NL-X ter2, none of which produces HBV X. Viruses were rescued from pHBV/NL-X ter1 and pHBV/NL-X ter2 by transfecting them into HepG2 together with pHBV/D. HepG2/NTCP#22
was infected with each virus fraction and NL activity was measured after 5 days of infection. NL activity of HBV/NL-X ter1 and HBV/ NL-X ter2 were 37 and 25% that of HBV/NL, respectively (Figure 4 Figure S2 ). It is thought that the association of hepadnavirus pgRNA with polymerase followed by reverse transcription of HBV pgRNA is efficient if polymerase is supplied in a cis-acting manner. 16 In this process, co-translated polymerase has a more efficient role compared with being supplied in trans from a helper virus. If this is the case, the efficiency of progeny virus production from HBV/NL may be low because of the lack of a pol gene.
We constructed a plasmid to produce recombinant HBV carrying the entire pol gene and NL gene, HBV/NL(S+pol) (Figure 1 ). HBV pol gene with a deletion in its spacer region was obtained from a patient treated with adefovir. 13 This deleted pol is functional in regard to catalyzing the synthesis of HBV DNA. 13 Thus, we also constructed pHBV/NL(S+polS) that has a deletion in the spacer region ( Figure 1 ).
The expression of virus RNA from plasmids transfected into
HepG2 cells is shown in Figure 6A . It is thought that the association of hepadnavirus pgRNA with polymerase followed by reverse transcription of HBV pgRNA is efficient if polymerase is supplied in a cis-acting manner. 16 In this pro- Hepatitis B virus X has a pivotal function in the transcription of virus RNA from HBV cccDNA. 21 Without the expression of HBV X, transcription is barely detectable. However, HBV/NL lacking X expression showed NL activity that was one-third or one-quarter that of HBV/NL in HepG2/NTCP#22. It is not known whether cellular factors that suppress transcription of HBV RNA are not recruited to the HBV/ NL cccDNA nucleosome structure 22 or whether HBV X incorporated into recombinant virus functions to support transcription. Further work is needed to clarify this point.
In summary, HBV/NL and its derivatives described here are useful for screening anti-HBV agents as well as exploring a variety of HBV replication strategies.
